Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of Trastuzumab and Etoposide for Her2 Positive Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Females or males with histologic confirmation of breast carcinoma and diagnosis of metastatic breast adenocarcinoma~* Confirmed HER2 amplification by immunohistochemical staining (IHC) 3+ or FISH amplified (either primary or metastatic).~* Have had any number of prior HER2 targeted therapy containing chemotherapies for treatment of breast cancer~* Measurable extent of disease~* Life expectancy of 3 months or greater~* Patients must have adequate heart function, determined with ECHO or MUGA (ECHO preferred).~* Patients must have adequate bone marrow and organ function~* Patient of childbearing potential must be willing to use an effective means of contraception during their participation on trial~* Greater than 3 weeks from prior radiation or chemotherapy; more than 1 week from prior hormonal therapy; and more than 6 weeks from prior treatment with nitrosoureas or mitomycin.~* No serious intercurrent medical illness.~* Controlled metastatic CNS disease ≥ 3 months~* The ability to understand and willingness to sign a written informed consent form, and to comply with the protocol.~Exclusion Criteria:~* Pregnant or nursing women~* Patients who are poor medical risk because of other non-malignant systemic disease or active, uncontrolled infection.~* Prior craniospinal radiation, or total body irradiation (TBI).~* Patients receiving G-CSF (filgrastim or pegfilgrastim) or thrombopoietin (or other platelet growth factors) within the 3 weeks prior to enrollment (erythropoietin is allowed).~* Prior chemotherapy within the last 3 weeks (last 6 weeks for nitrosureas/mitomycin).~* Prior radiation therapy within the last 3 weeks; prior radiation therapy to indicator lesion (unless objective disease recurrence or progression within the radiation portal has been documented since completion of radiation).~* Concomitant malignancies or previous malignancies within the last 5 years, with the exception of adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.~* Current symptoms of angina or uncontrolled arrhythmias, uncontrolled hypertension with systolic blood pressure \>=170 or diastolic blood pressure \>=110.~* Psychiatric illness precluding participation in study~* Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs, resulting in dyspnea at rest.~* Carcinomatous meningitis or CNS mets not controlled for ≥ 3 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single arm study (Type: EXPERIMENTAL): Etoposide 100mg/m2 daily x 3 days Q3W and Trastuzumab 8mg/kg loading dose then 6mg/kg, then single agent until disease progression

Based on this trial design, predict the completion outcome and termination type (if applicable).